Connect with us

News

Indigenous mRNA COVID-19 Vaccine Candidate Gets Drug Controller Nod To Initiate Human Clinical Trials

India’s first indigenous mRNA COVID-19 vaccine candidate has received approval from Indian Drug regulators to initiate Phase I/II human clinical trial

Indigenous mRNA COVID-19 Vaccine Candidate Gets Drug Controller Nod To Initiate Human Clinical Trials
Highlights
  • COVID-19 vaccine candidate uses prominent mutant of spike protein (D614G)
  • mRNA vaccines are fully synthetic and do not require a host for growth
  • mRNA vaccines can be quickly manufactured in an inexpensive manner

New Delhi: In a major development in the fight against COVID-19, India’s first indigenous mRNA vaccine candidate has received approval from Indian Drug regulators to initiate Phase I/II human clinical trial. The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune, and supported with a seed grant under the Ind-CEPI mission of the Department of Biotechnology of Union Ministry of Science and Technology. According to a release from the Ministry of Science and Technology, the mRNA vaccines do not use the conventional model to produce an immune response.

Also Read: There Has Been Absolutely No Compromise In Clinical Testing Of COVID-19 Vaccines: Gangandeep Kang, Clinical Scientist

Instead, mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus. The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease. The mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline, the release said.

The release said that the mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, for example, eggs or bacteria. Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their “availability” and “accessibility” for mass vaccination on a sustainable basis.

Gennova, in collaboration with HDT Biotech Corporation, Seattle, USA, has worked together to develop an mRNA vaccine candidate. HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activity in animals.

Also Read: Telangana Government Forms Four Committees For COVID-19 Vaccination Mechanism

The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19. Gennova’s vaccine candidate uses the most prominent mutant of spike protein (D614G) and also uses the self-amplifying mRNA platform, which gives the advantage of a low dosing regimen compared with the non-replicating mRNA or traditional vaccines. HGCO19 uses the adsorption chemistry so that the mRNA is attached on the surface of the nano-lipid carrier to enhance the release kinetics of the mRNA within the cells compared to the encapsulation chemistry, the release said.

HGCO19 is stable at 2-8degC for two months. Gennova has completed all preliminary work and should be initiating the Phase I/II Human clinical trial soon since the approval from the DCGI office has been received.

Also Read: Number Of COVID-19 Vaccines Growing But Volume Of Doses Remains Concern: World Health Organisation Adviser

The Department of Biotechnology is implementing the IndCEPImission ‘India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development’ which is aligned with the Global Initiative of CEPIand aims to strengthen the development of vaccines and associated competencies/technologies for the diseases of epidemic potential in India. The Ind-CEPI mission of DBT is implemented by its PSU, Biotechnology Industry Research Assistance Council (BIRAC).

Establishment of such indigenous technology platform will not only empower India to handle the COVID-19 pandemic but also ensure the preparedness for future outbreaks, said Dr RenuSwarup, Secretary, Department of Biotechnology and Chairperson BIRAC.

Also Read: Punjab Gears Up With Cold Chain Points For COVID-19 Vaccine

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published.

Folk Music For A Swasth India

RajasthanDay” src=

Reckitt’s Commitment To A Better Future

Expert Blog

हिंदी में पड़े

Latest Posts